Abstract: Fused [1,2]Imidazo[4,5-c] ring compounds (e.g., imidzao[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) substituted on the fused ring with a group that contains a guanidine or substituted guanidine moiety, pharmaceutical compositions containing the compounds, and methods of making the compounds are disclosed. Methods of use of the compounds as immune response modifiers, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are also disclosed.

Abstract: A process for separating aggregated proteins from monomeric proteins in a biological solution, the process including: providing at least one filter element having a contacting surface, wherein the filter element comprises filter media comprising: a porous substrate; and disposed on the porous substrate, a polymer comprising a hydrocarbon backbone and a plurality of pendant groups attached to the hydrocarbon backbone, wherein each of a first plurality of pendant groups comprises: (1) at least one acidic group or salt thereof; and (2) a spacer group that directly links the at least one acidic group or salt thereof to the hydrocarbon backbone by a chain of at least 6 catenated atoms; and allowing an initial biological solution to contact the contacting surface of the filter element N under conditions effective to separate the aggregated proteins from the monomeric proteins such that a final biological solution includes purified monomeric proteins.

Abstract: Guanidine-functionalized particles and methods of making and using such particles.

Abstract: Controlled radical initiators, reaction mixtures containing the controlled radical initiators and various ethylenically unsaturated monomers, and polymeric materials formed from the reaction mixtures are provided. The controlled radical initiators are bis-dithiocarbamate or bis-dithiocarbonate compounds with a single carbon atom between the two dithiocarbamate or dithiocarbonate groups. Polymeric materials such as homopolymers, random copolymers, and block copolymers can be prepared using the controlled radical initiators.

Abstract: A method of disinfecting a medical device comprises three steps. First, a disinfectant is contacted with a process indicator and the medical device. The disinfectant comprises at least one aldehyde. The process indicator contains a synthetic amine-containing compound disposed on a substrate. The synthetic amine-containing compound comprises at least one of primary amino groups or secondary amino groups, and is reactive with the disinfectant to form at least one adduct. The synthetic amine-containing compound and the medical device are in fluid communication through the disinfectant. A predetermined disinfectant exposure criterion exists for contacting the disinfectant with the medical device. Second, the process indicator is spectrally observed and at least one parameter is obtained therefrom that is predictive of the predetermined disinfectant exposure criterion. The third step is determining that the predetermined disinfectant exposure criterion has been achieved.

Abstract: Guanidine-functionalized particles and methods of making and using such particles.

Abstract: A process for preparing guanidino-functional, free radically polymerizable compounds comprises (a) combining (1) an amine compound comprising (i) at least one primary aliphatic amino group and (ii) at least one secondary aliphatic amino group, primary aromatic amino group, or secondary aromatic amino group, and (2) a guanylating agent; (b) allowing or inducing reaction of the amine compound and the guanylating agent to form a guanylated amine compound; (c) combining (1) the guanylated amine compound, and (2) a reactive monomer comprising (i) at least one ethylenically unsaturated group and (ii) at least one group that is reactive with an amino group; and (d) allowing or inducing reaction of the guanylated amine compound and the reactive monomer to form a guanidino-functional, free radically polymerizable compound.

Abstract: Polymeric materials are disclosed herein that include a Polymer A, a Polymer B, and an oxalate ester or reaction product thereof. Polymer A contains electrophilic reactive groups, and Polymer B contains nucleophilic groups. In certain embodiments, the polymeric materials are free-flowing liquids at 100% solids that can be used, for example, as topical skin adhesives.

Abstract: A substrate comprising a crosslinked polymer primer layer, and grafted thereto a ligand-functionalized polymer is provided. The grafted polymer has the requisite affinity for binding neutral or negatively charged biomaterials, such as cells, cell debris, bacteria, spores, viruses, nucleic acids, and proteins, at pH's near or below the pI's of the biomaterials.

Abstract: Imidazo[4,5-c] ring compounds, (particularly imidzao[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridine compounds) having a guanidine substituent at the 1-position, pharmaceutical compositions containing the compounds, and methods of making the compounds are disclosed. Methods of use of the compounds as immune response modifiers, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are also disclosed.

Abstract: Polymeric materials are disclosed herein that include a Polymer A, a Polymer B, and an oxalate ester or reaction product thereof. Polymer A contains electrophilic reactive groups, and Polymer B contains nucleophilic groups. In certain embodiments, the polymeric materials are free-flowing liquids at 100% solids that can be used, for example, as topical skin adhesives.

Abstract: Polymeric materials are disclosed herein that include a reaction product of components comprising: a) a first amine component having at least two and at most three primary amino groups, secondary amino groups, or a mixture thereof, with the proviso that the first amine component is not a silicone diamine; b) a second amine component having (i) greater than three primary amino groups, or (ii) at least three primary amino groups and a plurality of secondary amino groups, wherein the second amine component is a polymeric material having a carbon backbone or a polymeric material having a carbon backbone with a plurality of catenated nitrogen atoms; and c) an oxalate ester.

Abstract: Described herein is a polymer derived from (a) a fluorinated monomer selected from (i) CnF(2n+1)(CH2)zOC(?O)CR?CH2 wherein n is an integer selected from 1 to 8, z is an integer selected from 1 to 20, and R is H or CH3; and (ii) CnF(2n+1)SO2(NR?)(CH2)zOC(?O)CR?CH2 wherein n is an integer selected from 1 to 8; z is an integer selected from 2 to 20, and R is H or CH3 and R? is H or C1-C8 alkyl group; and (b) a monomer comprising a phosphonic moiety, along methods thereof and articles comprising such polymer.

Abstract: Polymeric materials are disclosed herein that include a reaction product of components comprising: a) a first amine component having at least two and at most three primary amino groups, secondary amino groups, or a mixture thereof, with the proviso that the first amine component is not a silicone diamine; b) a second amine component having (i) greater than three primary amino groups, or (ii) at least three primary amino groups and a plurality of secondary amino groups, wherein the second amine component is a polymeric material having a carbon backbone or a polymeric material having a carbon backbone with a plurality of catenated nitrogen atoms; and c) an oxalate ester.

Abstract: Imidazo[4,5-c] ring compounds, (particularly imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridine compounds) having a guanidine substituent at the 1-position, pharmaceutical compositions containing the compounds, and methods of making the compounds are disclosed. Methods of use of the compounds as immune response modifiers, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are also disclosed.

Abstract: A substrate comprising a crosslinked polymer primer layer, and grafted thereto a ligand-functionalized polymer is provided. The grafted polymer has the requisite affinity for binding neutral or negatively charged biomaterials, such as cells, cell debris, bacteria, spores, viruses, nucleic acids, and proteins, at pH's near or below the pI's of the biomaterials.

Abstract: The present invention provides an immune response modifier (IRM) composition that includes an IRM moiety and a second active moiety covalently linked to the IRM moiety, wherein the covalent link comprises a labile bond directly attached to the IRM moiety.

Abstract: A wipe article includes a substrate, a cationic coating disposed on a surface of the substrate, distributed throughout the substrate, or both. The cationic coating contains a guanidinyl-containing polymer that is crosslinked and bound to the substrate. The substrate includes sponge, nonwoven fabric, or woven fabric. The wipes are useful for removing microorganisms from a microorganism-contaminated surface and also for reducing re-contamination of the cleaned surface or transfer to another surface of the removed microorganisms.

Abstract: Imidazo[4,5-c] ring compounds, (particularly imidzao[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridine compounds) having a substituted guanidine substituent at the 1-position, pharmaceutical compositions containing the compounds, and methods of making the compounds are disclosed. Methods of use of the compounds as immune response modifiers, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are also disclosed.

Abstract: The present invention provides an immune response modifier (IRM) composition that includes an IRM moiety and a second active moiety covalently linked to the IRM moiety, wherein the covalent link comprises a labile bond directly attached to the IRM moiety.